Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor immune microenvironment (TIME) formed by interactions among cancer cells, immune cells, cancer-associated fibroblasts (CAF), and extracellular matrix (ECM) components drives PDAC in a more immunosuppre...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-023-02935-3 |
| _version_ | 1797349651890831360 |
|---|---|
| author | Wenyu Luo Ti Wen Xiujuan Qu |
| author_facet | Wenyu Luo Ti Wen Xiujuan Qu |
| author_sort | Wenyu Luo |
| collection | DOAJ |
| description | Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor immune microenvironment (TIME) formed by interactions among cancer cells, immune cells, cancer-associated fibroblasts (CAF), and extracellular matrix (ECM) components drives PDAC in a more immunosuppressive direction: this is a major cause of therapy resistance and poor prognosis. In recent years, research has advanced our understanding of the signaling mechanism by which TIME components interact with the tumor and the evolution of immunophenotyping. Through revolutionary technologies such as single-cell sequencing, we have gone from simply classifying PDACs as “cold” and “hot” to a more comprehensive approach of immunophenotyping that considers all the cells and matrix components. This is key to improving the clinical efficacy of PDAC treatments. In this review, we elaborate on various TIME components in PDAC, the signaling mechanisms underlying their interactions, and the latest research into PDAC immunophenotyping. A deep understanding of these network interactions will contribute to the effective combination of TIME-based therapeutic approaches, such as immune checkpoint inhibitors (ICI), adoptive cell therapy, therapies targeting myeloid cells, CAF reprogramming, and stromal normalization. By selecting the appropriate integrated therapies based on precise immunophenotyping, significant advances in the future treatment of PDAC are possible. |
| first_indexed | 2024-03-08T12:33:23Z |
| format | Article |
| id | doaj.art-72382f1e2d674f5abc49b46708166f7f |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-03-08T12:33:23Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-72382f1e2d674f5abc49b46708166f7f2024-01-21T12:39:45ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662024-01-0143113210.1186/s13046-023-02935-3Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the conceptWenyu Luo0Ti Wen1Xiujuan Qu2Department of Medical Oncology, The First Hospital of China Medical UniversityDepartment of Medical Oncology, The First Hospital of China Medical UniversityDepartment of Medical Oncology, The First Hospital of China Medical UniversityAbstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor immune microenvironment (TIME) formed by interactions among cancer cells, immune cells, cancer-associated fibroblasts (CAF), and extracellular matrix (ECM) components drives PDAC in a more immunosuppressive direction: this is a major cause of therapy resistance and poor prognosis. In recent years, research has advanced our understanding of the signaling mechanism by which TIME components interact with the tumor and the evolution of immunophenotyping. Through revolutionary technologies such as single-cell sequencing, we have gone from simply classifying PDACs as “cold” and “hot” to a more comprehensive approach of immunophenotyping that considers all the cells and matrix components. This is key to improving the clinical efficacy of PDAC treatments. In this review, we elaborate on various TIME components in PDAC, the signaling mechanisms underlying their interactions, and the latest research into PDAC immunophenotyping. A deep understanding of these network interactions will contribute to the effective combination of TIME-based therapeutic approaches, such as immune checkpoint inhibitors (ICI), adoptive cell therapy, therapies targeting myeloid cells, CAF reprogramming, and stromal normalization. By selecting the appropriate integrated therapies based on precise immunophenotyping, significant advances in the future treatment of PDAC are possible.https://doi.org/10.1186/s13046-023-02935-3Pancreatic ductal adenocarcinomaTumor microenvironmentImmunophenotypingIntegrated therapy |
| spellingShingle | Wenyu Luo Ti Wen Xiujuan Qu Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept Journal of Experimental & Clinical Cancer Research Pancreatic ductal adenocarcinoma Tumor microenvironment Immunophenotyping Integrated therapy |
| title | Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept |
| title_full | Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept |
| title_fullStr | Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept |
| title_full_unstemmed | Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept |
| title_short | Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept |
| title_sort | tumor immune microenvironment based therapies in pancreatic ductal adenocarcinoma time to update the concept |
| topic | Pancreatic ductal adenocarcinoma Tumor microenvironment Immunophenotyping Integrated therapy |
| url | https://doi.org/10.1186/s13046-023-02935-3 |
| work_keys_str_mv | AT wenyuluo tumorimmunemicroenvironmentbasedtherapiesinpancreaticductaladenocarcinomatimetoupdatetheconcept AT tiwen tumorimmunemicroenvironmentbasedtherapiesinpancreaticductaladenocarcinomatimetoupdatetheconcept AT xiujuanqu tumorimmunemicroenvironmentbasedtherapiesinpancreaticductaladenocarcinomatimetoupdatetheconcept |